Literature DB >> 30530757

Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

David M Kent1, Ewout Steyerberg2, David van Klaveren3,2.   

Abstract

The use of evidence from clinical trials to support decisions for individual patients is a form of "reference class forecasting": implicit predictions for an individual are made on the basis of outcomes in a reference class of "similar" patients treated with alternative therapies. Evidence based medicine has generally emphasized the broad reference class of patients qualifying for a trial. Yet patients in a trial (and in clinical practice) differ from one another in many ways that can affect the outcome of interest and the potential for benefit. The central goal of personalized medicine, in its various forms, is to narrow the reference class to yield more patient specific effect estimates to support more individualized clinical decision making. This article will review fundamental conceptual problems with the prediction of outcome risk and heterogeneity of treatment effect (HTE), as well as the limitations of conventional (one-variable-at-a-time) subgroup analysis. It will also discuss several regression based approaches to "predictive" heterogeneity of treatment effect analysis, including analyses based on "risk modeling" (such as stratifying trial populations by their risk of the primary outcome or their risk of serious treatment-related harms) and analysis based on "effect modeling" (which incorporates modifiers of relative effect). It will illustrate these approaches with clinical examples and discuss their respective strengths and vulnerabilities. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Year:  2018        PMID: 30530757      PMCID: PMC6889830          DOI: 10.1136/bmj.k4245

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  132 in total

1.  More on subgroup analyses in clinical trials.

Authors:  Stuart J Pocock; Jacobus Lubsen
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

2.  Realizing the Potential of Clinical Risk Prediction Models: Where Are We Now and What Needs to Change to Better Personalize Delivery of Care?

Authors:  Adam C Salisbury; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-07-07

3.  The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects.

Authors:  David van Klaveren; Ewout W Steyerberg; Patrick W Serruys; David M Kent
Journal:  J Clin Epidemiol       Date:  2017-11-11       Impact factor: 6.437

4.  Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty.

Authors:  Jens Jakob Thune; Dan Eik Hoefsten; Matias Greve Lindholm; Leif Spange Mortensen; Henning Rud Andersen; Torsten Toftegaard Nielsen; Lars Kober; Henning Kelbaek
Journal:  Circulation       Date:  2005-09-27       Impact factor: 29.690

5.  How to translate clinical trial results into gain in healthy life expectancy for individual patients.

Authors:  Jannick A N Dorresteijn; Lotte Kaasenbrood; Nancy R Cook; Rob C M van Kruijsdijk; Yolanda van der Graaf; Frank L J Visseren; Paul M Ridker
Journal:  BMJ       Date:  2016-03-30

6.  When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?

Authors:  Jessica M Franklin; Sebastian Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2017-09-25       Impact factor: 6.875

7.  Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group.

Authors:  G H Guyatt; D L Sackett; D J Cook
Journal:  JAMA       Date:  1994-01-05       Impact factor: 56.272

8.  Assessing apparent treatment--covariate interactions in randomized clinical trials.

Authors:  D P Byar
Journal:  Stat Med       Date:  1985 Jul-Sep       Impact factor: 2.373

9.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

10.  Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.

Authors:  Peter W F Wilson; James B Meigs; Lisa Sullivan; Caroline S Fox; David M Nathan; Ralph B D'Agostino
Journal:  Arch Intern Med       Date:  2007-05-28
View more
  78 in total

1.  N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?

Authors:  Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

2.  CORR Insights®: Is There a Difference in Infection Risk Between Single and Multiple Doses of Prophylactic Antibiotics? A Meta-analysis.

Authors:  Gerard P Slobogean
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

3.  Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death.

Authors:  Susanna F Fustolo-Gunnink; Karin Fijnvandraat; David van Klaveren; Simon J Stanworth; Anna Curley; Wes Onland; Ewout W Steyerberg; Ellen de Kort; Esther J d'Haens; Christian V Hulzebos; Elise J Huisman; Willem P de Boode; Enrico Lopriore; Johanna G van der Bom
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

4.  Predicting preventable hospital readmissions with causal machine learning.

Authors:  Ben J Marafino; Alejandro Schuler; Vincent X Liu; Gabriel J Escobar; Mike Baiocchi
Journal:  Health Serv Res       Date:  2020-10-30       Impact factor: 3.402

5.  Could stress ulcer prophylaxis increase mortality in high-acuity patients?

Authors:  Michael O Harhay; Paul J Young; Manu Shankar-Hari
Journal:  Intensive Care Med       Date:  2020-02-19       Impact factor: 17.440

6.  Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial.

Authors:  Anders Granholm; Søren Marker; Mette Krag; Fernando G Zampieri; Hans-Christian Thorsen-Meyer; Benjamin Skov Kaas-Hansen; Iwan C C van der Horst; Theis Lange; Jørn Wetterslev; Anders Perner; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2020-01-14       Impact factor: 17.440

7.  Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.

Authors:  Natalia Olchanski; David van Klaveren; Joshua T Cohen; John B Wong; Robin Ruthazer; David M Kent
Journal:  Acta Diabetol       Date:  2021-01-30       Impact factor: 4.280

8.  Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial.

Authors:  Tamar I de Vries; Jannick A N Dorresteijn; Yolanda van der Graaf; Frank L J Visseren; Jan Westerink
Journal:  Diabetes Care       Date:  2019-08-15       Impact factor: 19.112

9.  Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.

Authors:  Jacob Spertus; Marcela Horvitz-Lennon; Sharon-Lise T Normand
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

Review 10.  Artificial intelligence for retinopathy of prematurity.

Authors:  Rebekah H Gensure; Michael F Chiang; John P Campbell
Journal:  Curr Opin Ophthalmol       Date:  2020-09       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.